Top Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filingrttnews·Jul 21 at 10:25 PMASBP-3.99%DYAI-5.04%
Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price TargetTip Ranks·Jul 21 at 03:19 PMPVLA+2.72%
Palvella Therapeutics (PVLA) Receives a Rating Update from a Top AnalystTip Ranks·Jul 21 at 11:26 AMPVLA+2.72%
Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $642,194.57PUBT·Jul 17 at 03:06 PMPVLA+2.72%
Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cashTradingView·Jul 14 at 03:54 PMPVLA+2.72%
Palvella Therapeutics director Matthew Pauls files initial beneficial ownership statementPUBT·Jul 1 at 03:06 PMPVLA+2.72%
Palvella Therapeutics appoints Savara CEO Matt Pauls to board of directorsPUBT·Jun 30 at 06:31 AMPVLA+2.72%
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic MalformationsUnusual Whales·Jun 29 at 06:31 AMPVLA+2.72%
Palvella submits first NDA module to FDA for QTORIN rapamycin under rolling reviewPUBT·Jun 29 at 06:30 AMPVLA+2.72%
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & Morerttnews·Jun 24 at 09:09 AMINBX+1.10%PVLA+2.72%
Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71PUBT·Jun 22 at 04:07 PMPVLA+2.72%
Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)Tip Ranks·Jun 22 at 08:45 AMPVLA+2.72%
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations | PVLA Stock NewsStockTitan·Jun 21 at 10:30 PMPVLA+2.72%
